Tag: breast

Premenopausal women with hormone receptor-positive, HER2-negative breast cancer and a high risk of recurrence who are treated with an aromatase inhibitor plus ovarian function suppression may gain 10 to 15 percent improvement in freedom from distant recurrence at eight years, according to a new clinical trial analysis reported at the annual meeting of the American

The combination of taselisib and fulvestrant has shown to slow the growth of cancer in post-menopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER2) negative, PIK3CA-mutant, inoperable, locally advanced or metastatic breast cancer. Researchers from Memorial Sloan Kettering Cancer Center (MSK) presented this data, from the SANDPIPER trial, in a press conference

Mother with incurable breast cancer is forced to raise £1,000 each month for a drug not available on the NHS because she ‘is not ready’ to say goodbye to her three children Lesley Kennedy, of Belfast, is now taking palbociclib to keep her alive for longer It is hailed as the ‘closest thing to a

DNA is the warehouse of genetic information in each living cell, and its integrity and stability are essential to life. This stability and integrity is maintained by DNA damage repair machinery. In a study published in Clinical Cancer Research, a research team at Baylor College of Medicine found that defects in selective DNA damage repair

In a BJS (British Journal of Surgery) analysis of 18,730 older patients with oestrogen receptor- positive breast cancer in the UK, the risk of dying from breast cancer was greater in patients treated with primary endocrine therapy than in those who received surgery. For the study, researchers analysed cancer registration data from two English regions

In a recent study published in the Journal of Clinical Investigation, Mayo Clinic researchers identified that an FDA drug approved for myelodysplastic syndrome may be useful to treat triple-negative breast cancer, which is one of the most aggressive and lethal types of breast cancer. In this study, Mayo investigators identified that the drug 5-aza-2′-deoxycytidine (decitabine)

Although the genitourinary syndrome of menopause (GSM) is more prevalent in survivors of breast cancer than in other menopausal women, it is commonly undiagnosed and untreated. This led The North American Menopause Society (NAMS) and The International Society for the Study of Women’s Sexual Health (ISSWSH) to form a multidisciplinary Consensus Panel to develop recommendations

Many women with a common and aggressive form of breast cancer that is treated with Herceptin can get by with six months of the drug instead of the usual 12, greatly reducing the risk of heart damage it sometimes can cause, a study suggests. It’s good news, but it comes nearly two decades after the

Genome-wide association studies (GWAS) have identified more than 150 genetic variations associated with increased risk for breast cancer. Most of these variants are not located in protein-coding gene regions but are assumed to regulate the expression of certain genes. One way to figure out what these variants are doing is to conduct a cis-eQTL analysis.

Move every day, cut down on oil and stick to one glass of wine: Proven things that DO lower your risk of breast cancer One in eight women will be diagnosed with breast cancer during her lifetime But there are steps you can take to reduce your risk of the deadly disease Exercising at least

Women with an aggressive form of breast cancer who have faults in their BRCA genes do much better on chemotherapy drug carboplatin than standard treatment, a major clinical trial reports. Researchers found that women with advanced ‘triple-negative’ breast cancer who had inherited a BRCA mutation were twice as likely to benefit from carboplatin as docetaxel,

A study performed by an international team led by the Barcelona Institute for Global Health (ISGlobal), a centre supported by the “la Caixa” Foundation, reports a link between exposure to blue light at night and higher risk of developing breast and prostate cancer. Blue light is a range of the visible light spectrum emitted by

After surgery for breast cancer women who have undergone breast reconstruction using abdominal tissue do not have a higher risk of recurrence than women who do not undergo breast reconstruction. This has been shown by researchers at Karolinska Institutet in a study published in the British Journal of Surgery. In Sweden today, more than 90,000

Six in seven women with a family history of breast cancer opt out of taking tamoxifen as a preventative measure, according to a study funded by Cancer Research UK and published in Breast Cancer Research and Treatment today. Researchers asked 258 healthy women across England who had been identified as having an increased risk of

Difficult to treat and aggressive “triple-negative” breast cancer is chemoresistant even before chemotherapy begins, a new study by researchers from Karolinska Institutet and the University of Texas MD Anderson Cancer Center reports. The findings, which are published in the journal Cell, may lead to better and more personalised treatments for breast cancer. Breast cancer is

Researchers at UT Southwestern Medical Center have identified a protein that is strongly associated with metastatic breast cancer and that could be a target for future therapies. High levels of the protein ZMYND8 are correlated with poor survival in breast cancer patients, said Dr. Weibo Luo, Assistant Professor of Pathology and Pharmacology, and with the

(HealthDay)—For patients with breast cancer, endocrine therapy-induced alopecia (EIA) has a pattern that is similar to androgenetic alopecia, according to a study published online April 11 in JAMA Dermatology. Azael Freites-Martinez, M.D., from the Memorial Sloan Kettering Cancer Center in New York City, and colleagues conducted a retrospective cohort study to characterize EIA in 112

A multi-institutional research team has identified what may be a novel mechanism underlying acquired resistance to CDK 4/6 inhibitor treatment for breast cancer. In their report published in the Annals of Oncology, the team—led by investigators at Massachusetts General Hospital (MGH), Institute Gustave Roussy in Paris, and Texas Oncology-Baylor Sammons Cancer Center/U.S. Oncology in Dallas—reports